How the lab is changing our view of colorectal cancer

被引：8

作者：

Cremolini, Chiara ^{[1
]}

Pietrantonio, Filippo ^{[2
]}

机构：

[1] Univ Pisa, Dept Oncol, Univ Hosp Pisa, Tuscan Tumor Inst, Pisa, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

TUMORI JOURNAL | 2016年 / 102卷 / 06期

关键词：

Biomarkers; Colorectal cancer; Precision medicine; FOLFOXIRI PLUS BEVACIZUMAB; PHASE-II; MICROSATELLITE INSTABILITY; PREDICTIVE BIOMARKER; 1ST-LINE TREATMENT; ANTIBODY THERAPY; BRAF MUTATION; IMMUNE CELLS; TEMOZOLOMIDE; GENE;

D O I：

10.5301/tj.5000551

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In metastatic colorectal cancer, the optimization of upfront treatment and the continuum of care based on patients' exposure to multiple treatment lines have reached a plateau of efficacy. Therefore, a paradigm shift is ongoing towards precision medicine and personalized treatments based on the specific molecular features of the disease. In this perspective, the improved knowledge of disease biology coming from the lab has prompted a rapid translation from bench to bedside of newer targeted strategies. Here, we focus on the most promising biomarkers already included or close to adoption in daily clinical practice. In particular, evidence about the potential roles of BRAF mutation, HER2 amplification, MGMT methylation, microsatellite instability, and ALK, ROS and NTRK1-3 rearrangements as positive predictors of benefit from biological agents is reviewed and discussed.

引用

页码：541 / 547

页数：7

共 70 条

[1] ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers [J].

Aisner, Dara L. ;

Nguyen, Teresa T. ;

Paskulin, Diego D. ;

Le, Anh T. ;

Haney, Jerry ;

Schulte, Nathan ;

Chionh, Fiona ;

Hardingham, Jenny ;

Mariadason, John ;

Tebbutt, Niall ;

Doebele, Robert C. ;

Weickhardt, Andrew J. ;

Varella-Garcia, Marileila .

MOLECULAR CANCER RESEARCH, 2014, 12 (01) :111-118

[2] Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer [J].

Amatu, A. ;

Barault, L. ;

Moutinho, C. ;

Cassingena, A. ;

Bencardino, K. ;

Ghezzi, S. ;

Palmeri, L. ;

Bonazzina, E. ;

Tosi, F. ;

Ricotta, R. ;

Cipani, T. ;

Crivori, P. ;

Gatto, R. ;

Chirico, G. ;

Marrapese, G. ;

Truini, M. ;

Bardelli, A. ;

Esteller, M. ;

Di Nicolantonio, F. ;

Sartore-Bianchi, A. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2016, 27 (06) :1062-1067

[3] Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer [J].

Amatu, Alessio ;

Somaschini, Alessio ;

Cerea, Giulio ;

Bosotti, Roberta ;

Valtorta, Emanuele ;

Buonandi, Pasquale ;

Marrapese, Giovanna ;

Veronese, Silvio ;

Luo, David ;

Hornby, Zachary ;

Multani, Pratik ;

Murphy, Danielle ;

Shoemaker, Robert ;

Lauricella, Calogero ;

Giannetta, Laura ;

Maiolani, Martina ;

Vanzulli, Angelo ;

Ardini, Elena ;

Galvani, Arturo ;

Isacchi, Antonella ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore .

BRITISH JOURNAL OF CANCER, 2015, 113 (12) :1730-1734

[4] Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer [J].

Amatu, Alessio ;

Sartore-Bianchi, Andrea ;

Moutinho, Catia ;

Belotti, Alessandro ;

Bencardino, Katia ;

Chirico, Giuseppe ;

Cassingena, Andrea ;

Rusconi, Francesca ;

Esposito, Anna ;

Nichelatti, Michele ;

Esteller, Manel ;

Siena, Salvatore .

CLINICAL CANCER RESEARCH, 2013, 19 (08) :2265-2272

[5]

[Anonymous], J CLIN ONCOL S5S

[6] Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer [J].

Barault, L. ;

Amatu, A. ;

Bleeker, F. E. ;

Moutinho, C. ;

Falcomata, C. ;

Fiano, V. ;

Cassingena, A. ;

Siravegna, G. ;

Milione, M. ;

Cassoni, P. ;

De Braud, F. ;

Ruda, R. ;

Soffietti, R. ;

Venesio, T. ;

Bardelli, A. ;

Wesseling, P. ;

Hamer, P. de Witt ;

Pietrantonio, F. ;

Siena, S. ;

Esteller, M. ;

Sartore-Bianchi, A. ;

Di Nicolantonio, F. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1994-1999

[7] Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). [J].

Bendell, Johanna C. ;

Kim, Tae Won ;

Goh, Boon C. ;

Wallin, Jeffrey ;

Oh, Do-Youn ;

Han, Sae-Won ;

Lee, Carrie B. ;

Hellmann, Matthew David ;

Desai, Jayesh ;

Lewin, Jeremy Howard ;

Solomon, Benjamin J. ;

Chow, Laura Quan Man ;

Miller, Wilson H. ;

Gainor, Justin F. ;

Flaherty, Keith ;

Infante, Jeffrey R. ;

Das-Thakur, Meghna ;

Foster, Paul ;

Cha, Edward ;

Bang, Yung-Jue .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[8] Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). [J].

Bendell, Johanna C. ;

Atreya, Chloe Evelyn ;

Andre, Thierry ;

Tabernero, Josep ;

Gordon, Michael S. ;

Bernards, Rene ;

Van Cutsem, Eric ;

Tejpar, Sabine ;

Sidhu, Roger ;

Go, William Y. ;

Allred, Alicia ;

Motwani, Monica ;

Suttle, Benjamin B. ;

Wu, Yuehui ;

Hoos, Axel ;

Orford, Keith W. ;

Corcoran, Ryan Bruce ;

Schellens, Jan H. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[9] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer [J].

Bertotti, Andrea ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Sassi, Francesco ;

Torti, Davide ;

Isella, Claudio ;

Cora, Davide ;

Di Nicolantonio, Federica ;

Buscarino, Michela ;

Petti, Consalvo ;

Ribero, Dario ;

Russolillo, Nadia ;

Muratore, Andrea ;

Massucco, Paolo ;

Pisacane, Alberto ;

Molinaro, Luca ;

Valtorta, Emanuele ;

Sartore-Bianchi, Andrea ;

Risio, Mauro ;

Capussotti, Lorenzo ;

Gambacorta, Marcello ;

Siena, Salvatore ;

Medico, Enzo ;

Sapino, Anna ;

Marsoni, Silvia ;

Comoglio, Paolo M. ;

Bardelli, Alberto ;

Trusolino, Livio .

CANCER DISCOVERY, 2011, 1 (06) :508-523

[10] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

← 1 2 3 4 5 6 7 →